LY6K Antibody is affinity chromatography purified via peptide column.
Immunogen
LY6K antibody was raised against an 18 amino acid synthetic peptide near the amino terminus of human LY6K. The immunogen is located within the first 50 amino acids of LY6K.
Ly6k
Reaktivität: Human
ELISA, FACS
Wirt: Maus
Monoclonal
750747
unconjugated
Applikationshinweise
LY6K antibody can be used for detection of LY6K by Western blot at 1 - 2 μ,g/mL.
Antibody validated: Western Blot in human samples. All other applications and species not yet tested.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
LY6K Antibody is supplied in PBS containing 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C,4 °C
Informationen zur Lagerung
LY6K antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
Ly6k
(Lymphocyte Antigen 6 Complex, Locus K (Ly6k))
LY6K antikoerper, CT97 antikoerper, HSJ001348 antikoerper, ly-6K antikoerper, 2410015A16Rik antikoerper, 3110035B01Rik antikoerper, mLy-6K antikoerper, lymphocyte antigen 6 family member K antikoerper, lymphocyte antigen 6 complex, locus K antikoerper, LY6K antikoerper, Ly6k antikoerper
Hintergrund
LY6K Antibody: The lymphocyte antigen 6 complex locus K (LY6K), a member of cancer-testis antigen was initially identified as a molecular marker for head-and-neck squamous cell carcinoma as well a breast cancer. LY6K is a GPI-anchored membrane protein that is specifically associated with germ cell marker TEX101 and is strongly observed in testis, but only weakly in other tissues. LY6K mRNA was found to be upregulated in numerous bladder cancers due to gene amplification. Furthermore, knockdown experiments using LY6K siRNA reduced cell growth, migration and invasion in bladder carcinoma cell lines, suggesting that LY6K contributes to bladder cancer development.